Coherus Oncology (CHRS) Intangibles (2014 - 2026)
Coherus Oncology (CHRS) posted Intangibles of $26.2 million for Q1 2026, little changed sequentially from $26.2 million in Q4 2025, and down 9.08% YoY from $28.9 million in Q1 2025.
Coherus Oncology (CHRS) Intangibles (2014 - 2026) Analysis & Trends
Coherus Oncology has reported Intangibles for 13 years, with the latest figure at $26.2 million in Q1 2026.
- Quarterly Intangibles fell 9.08% year-over-year to $26.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $26.2 million (down 9.08% YoY) and the FY2025 annual result came in at $26.2 million, down 9.08% from the prior year.
- Intangibles steadied at $26.2 million in Q1 2026 per CHRS's latest filing, from $26.2 million in the prior quarter.
- Over five years, Intangibles peaked at $41.9 million in Q4 2023 and troughed at $1.6 million in Q3 2025.
- A 5-year average of $22.5 million and a median of $26.2 million in 2025 frame the typical range for Intangibles.
- The sharpest annual moves came in 2023 and 2025: Intangibles surged 605.97% in 2023, then plunged 93.71% in 2025.
- Over 5 years, Intangibles stood at $5.9 million in 2022, then soared by 605.97% to $41.9 million in 2023, then sank by 31.08% to $28.9 million in 2024, then retreated by 9.08% to $26.2 million in 2025, then changed by 0.0% to $26.2 million in 2026.
- According to Business Quant data, Intangibles over the past three periods registered $26.2 million, $26.2 million, and $1.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 412.80 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.31 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 266.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 60.96 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 93.49 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Coherus Oncology | 221.39 Mn | 116.08 Mn | 10.07 Mn | 26.24 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 26.24 Mn |
| Mar 31, 2026 | 26.24 Mn |
| Dec 31, 2025 | 26.24 Mn |
| Sep 30, 2025 | 1.60 Mn |
| Jun 30, 2025 | 28.86 Mn |
| Mar 31, 2025 | 28.86 Mn |
| Dec 31, 2024 | 28.86 Mn |
| Sep 30, 2024 | 25.45 Mn |
| Jun 30, 2024 | 28.86 Mn |
| Mar 31, 2024 | 10.60 Mn |
| Dec 31, 2023 | 41.87 Mn |
| Sep 30, 2023 | 16.72 Mn |
| Dec 31, 2022 | 5.93 Mn |
| Dec 31, 2021 | 3.56 Mn |
| Sep 30, 2021 | 2.62 Mn |
| Jun 30, 2021 | 2.62 Mn |
| Mar 31, 2021 | 2.62 Mn |
| Dec 31, 2020 | 2.62 Mn |
| Sep 30, 2020 | 2.62 Mn |
| Jun 30, 2020 | 2.62 Mn |